Key result
Elevated Lp(a) linked to ~31% higher MACE risk in patients with ischemic heart disease.
Why the study?
Lipoprotein(a) has emerged as a significant cardiovascular risk factor, particularly in patients with ischemic heart disease, but comprehensive synthesized evidence on its clinical impact was needed.
Does elevated Lipoprotein(a) increase the risk of major adverse cardiovascular events in patients with ischemic heart disease?
Meta-Analysis (n=62,247)
Yes
Does elevated Lipoprotein(a) increase the risk of major adverse cardiovascular events in patients with ischemic heart disease?
Effect estimate: HR 1.31 (95% CI 1.19-1.45)
p-value: p=0.002
Elevated Lipoprotein(a) levels are significantly associated with an increased risk of adverse cardiovascular outcomes, including MACE and mortality, in patients with ischemic heart disease.
May aid Lp(a) testing for risk stratification in IHD; reinforces its prognostic value in meta-analyses of observational data.
Lipoprotein(a) (Lp(a)) has emerged as a significant cardiovascular risk factor, particularly in patients with ischemic heart disease (IHD). This systematic review and meta-analysis aimed to synthesize evidence on the impact of Lp(a) levels on cardiovascular outcomes in IHD patients. A comprehensive literature search was conducted across multiple databases, covering publications from January 2016 to October 2024. Studies assessing the relationship between Lp(a) levels and cardiovascular outcomes in IHD patients were included. The primary outcomes were major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction, and revascularization. Quality assessment was performed using the Newcastle-Ottawa Scale. Fourteen studies (five prospective, nine retrospective) met the inclusion criteria, with sample sizes ranging from 350 to 18,544 participants. Pooled analysis revealed that elevated Lp(a) levels were significantly associated with increased risk of MACE (HR: 1.31, 95% CI: 1.19-1.45), all-cause mortality (HR: 1.23, 95% CI: 1.15-1.31), myocardial infarction (HR: 1.20, 95% CI: 1.06-1.35), and revascularization (HR: 1.23, 95% CI: 1.08-1.39) in IHD patients. Sensitivity analyses confirmed the robustness of these findings. This meta-analysis provides strong evidence that elevated Lp(a) levels are associated with adverse cardiovascular outcomes in IHD patients. The findings underscore the potential role of Lp(a) as an important prognostic marker and suggest that incorporating Lp(a) assessment into clinical practice could enhance risk stratification. Future research should focus on establishing optimal Lp(a) cutoff values and evaluating the impact of Lp(a)-lowering therapies on cardiovascular outcomes in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Hamid et al. (2024) conducted a meta-analysis in Ischemic heart disease (n=62,247). Elevated Lipoprotein(a) vs. Lower Lipoprotein(a) was evaluated on Major adverse cardiovascular events (MACE) (HR 1.31, 95% CI 1.19-1.45, p=0.002). Elevated Lipoprotein(a) levels significantly increased the risk of major adverse cardiovascular events (HR 1.31) in patients with ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: